Characteristics and Prognostic Outcomes of Diaphragmatic Ultrasound in Myasthenia Gravis
1 other identifier
observational
100
1 country
1
Brief Summary
The goal of this observational study is to learn about the characteristics and prognostic outcomes of diaphragmatic ultrasound in myasthenia gravis. The main question it aims to answer is: Does diaphragmatic ultrasound predict prognosis of myasthenia gravis in six months? Participants diagnosed as myasthenia gravis will take the diaphragm ultrasound examinations.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jul 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2024
CompletedFirst Submitted
Initial submission to the registry
November 25, 2024
CompletedFirst Posted
Study publicly available on registry
November 27, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2026
ExpectedNovember 27, 2024
November 1, 2024
1.5 years
November 25, 2024
November 25, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
QMG changes
6 months
Secondary Outcomes (2)
Changes in medication type or dose
6 months
respiratory infection
6 months
Study Arms (2)
myasthenia gravis
controls
Eligibility Criteria
Patients who seek treatment at the First Affiliated Hospital of Chongqing Medical University and have fluctuating skeletal muscle weakness and at least one of the following three conditions will be included: positive reaction to cholinesterase inhibitors; Serum positive antibodies against acetylcholine receptors, muscle specific kinases, or lipoprotein related proteins; Repeated electrical stimulation examination showed a decrease in wave amplitude.
You may qualify if:
- : Patients who seek treatment at the First Affiliated Hospital of Chongqing Medical University and have fluctuating skeletal muscle weakness and at least one of the following three conditions will be included: positive reaction to cholinesterase inhibitors
- : Serum positive antibodies against acetylcholine receptors, muscle specific kinases, or lipoprotein related proteins
- : Repeated electrical stimulation examination showed a decrease in wave amplitude.
You may not qualify if:
- : Patients with lung disease or heart failure, or a history of non-invasive ventilator or tracheotomy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, 400016, China
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 6 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof.Fei Xiao
Study Record Dates
First Submitted
November 25, 2024
First Posted
November 27, 2024
Study Start
July 1, 2024
Primary Completion
December 31, 2025
Study Completion (Estimated)
June 30, 2026
Last Updated
November 27, 2024
Record last verified: 2024-11
Data Sharing
- IPD Sharing
- Will share